Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery 73% Improvement Relative Risk c19early.org/j Alizadeh et al. Melatonin for COVID-19 RCT EARLY TREATMENT Is early treatment with melatonin beneficial for COVID-19? RCT 31 patients in Iran Improved recovery with melatonin (not stat. sig., p=0.057) Alizadeh et al., Iranian J. Allergy, Asthma and Immunology Favors melatonin Favors control
A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement
Alizadeh et al., Iranian Journal of Allergy, Asthma and Immunology
Alizadeh et al., A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement, Iranian Journal of Allergy, Asthma and Immunology
May 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT 31 mild/moderate COVID-19 outpatients in Iran, 14 treated with melatonin, showing improved recovery with treatment.
risk of no recovery, 73.0% lower, RR 0.27, p = 0.06, treatment 2 of 14 (14.3%), control 9 of 17 (52.9%), NNT 2.6, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Alizadeh et al., 29 May 2021, Single Blind Randomized Controlled Trial, Iran, peer-reviewed, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: BRIEF COMMUNICATION Iran J Allergy Asthma Immunol In press. A Pilot Study on Controlling Coronavirus Disease 2019 (COVID-19) Inflammation Using Melatonin Supplement Zahra Alizadeh1, Nastaran Keyhanian2, Sara Ghaderkhani2, Simin Dashti-Khavidaki3, Raheleh Shokouhi Shoormasti1, and Zahra Pourpak1 1 Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran 2 Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran 3 Department of Pharmacology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran Received: 2 January 2021; Received in revised form: 1 April 2021; Accepted: 10 April 2021 ABSTRACT No effective antiviral drugs and vaccines are available for the treatment of patients with severe coronavirus 2019 (COVID-19). Therefore, available, safe, and inexpensive drugs and supplements such as melatonin are among the proposed options for controlling inflammation. We did a randomized, single-blind study in Imam Khomeini Hospital between June 30, 2020, and August 5, 2020. Mild to moderate COVID-19 patients aged 25-65 years were eligible to enter the study based on chest CT scan, clinical symptoms, and physician diagnosis. The intervention group was prescribed 6 mg of oral melatonin for 2 weeks, which consumed half an hour before bedtime every night in low light conditions. Clinical symptoms and Creactive protein (CRP) were measured before and after treatment in the melatonin received and control (regular medications) groups. among screened patients with COVID-19, 14 patients were assigned to receive melatonin, and 17 patients were considered as controls. A significant difference (p=0.005) between CRP 1 and CRP 2 levels (before and after using melatonin) was found in the melatonin group while this difference (p=0.069) was not significant in the control group. Also, the percentage of recovery (based on symptoms) in patients who took melatonin was higher than that of patients in the control group (85.7% VS 47.1%). The result of this study confirmed the effectiveness of melatonin in mild to moderate outpatients with COVID-19. More clinical trials on elderly, diabetic, obese patients and severe cases are suggested in future studies. Keywords: COVID-19; Inflammation; Melatonin Corresponding Author: Zahra Alizadeh, PhD; Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Tel: (+98 912) 7184 258, Fax: (+98 21) 6642 8995, E-mail: z-Alizadehs@farabi.tums.ac.ir
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit